Business
Amgen To Webcast Investor Meeting At 55th Annual Meeting Of The American Society Of Clinical Oncology (ASCO)
THOUSAND OAKS, Calif., May 29, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will host a webcast investor meeting at ASCO 2019 on Monday, June 3 at 6:30 p.m. CT.
About this update from Amgen Inc.
[{"type":"text","content":"THOUSAND OAKS, Calif., May 29, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will host a webcast investor meeting at ASCO 2019 on Monday, June 3 at 6:30 p.m. CT. David M. Reese, M.D., executive vice president of Research and Development at Amgen, along with members of Amgen's clinical development team and clinical investigators, will participate at the investor meeting to discuss Amgen's oncology program and data presented at ASCO 2019 including clinical data being presented for the Company's KRAS G12C inhibitor AMG 510 and BiTE® molecules AMG 420 and AMG 212. \nLive audio of the investor meeting will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public. \nThe webcast, as with other selected presentations regarding developments in Amgen's business given at certain investor and medical conferences, can be accessed on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event. \nAbout AmgenAmgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.\nAmgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.\nFor more information, visit www.amgen.com and follow us on www.twitter.com/amgen.\nCONTACT: Amgen, Thousand OaksKristen Davis, 805-447-3008 (media)Jessica Akopyan, 805-447-0974 (media) Arvind Sood, 805-447-1060 (investors)\n \n\n\n\n View original content to download multimedia:http://www.prnewswire.com/news-releases/amgen-to-webcast-investor-meeting-at-55th-annual-meeting-of-the-american-society-of-clinical-oncol...